The new era of HIV prevention is officially here. With the recent approval of Renacapavil by the FDA, a groundbreaking infusion-able preparation that requires only two doses a year, Misttr is ready to prepare its first national platform, large, free and with no red tape.
For those unfamiliar with the name, Renacapavir (sold as Yeztugo) is a long-acting, injectable treatment that it offers up to. 99% protection against HIV just Two subcutaneous shots per year. It’s not only a medical breakthrough, but a lifestyle shift for thousands of people that are burdened by daily or bimonthly preparation regimens.
“The Renakapaville is a true game changer,” said Tristan Schukraft, founder and CEO of Misttr. “It’s modest, easy and built for real life. Its simplicity means that more people can actually continue to prepare.
Is the Renacapaville a big deal?
Unlike previous injections, lenacapavir is administered Subcutaneously, Not through painful intramuscular shots, but with belly fat. The reduction in discomfort combined with the ultra-low frequency of injections makes it a highly accessible option for individuals facing barriers such as unstable housing, stigma, or limited access to consistent care.
“For those dealing with stigma and access to unstable health care, two-shots per year can literally mean a difference between protection and risk,” Schcraft said. “And once you get it from Mistr, it’s completely free.”
Mistr’s “no barrier” model
Misttr is uniquely positioned to lead the development of the Renacapaville thanks to its hybrid model, a fusion of national telehealth access and localized face-to-face care. The platform operates seven major LGBTQ+ storefronts.
-
West Hollywood (Los Angeles)
-
Castro (San Francisco)
-
Hell’s Kitchen (New York City)
-
Wilton Manor (Fort Lauderdale)
-
Northalstead (Chicago)
-
Oak Lawn (Dallas)
-
Las Vegas
For patients outside these hubs, Misttr activated the network Community-based providers over 65 years old To ensure national compensation. However, accessibility is not merely geographical, it is economical.
“We are the only national telehealth platform that completely frees PREP for patients who are not covered by insurance,” Schcraft explained. “Around 70% of our patients are insured and preparing through us helps to cover the 30% costs that we don’t.
Even in the case of insured persons, No co-payment, no surprise bills, no headaches with documents. Mistr takes care of everything including qualifications, lab work, doctor visits, scheduling, follow-up and more.
Public health that fills the gap remains behind
As public health budgets face increasing cuts, Mistr has proven that private platforms can step on places where systems are scarce.
“With public programs under attack, we have shown that we can serve more than half a million people without having to charge the government or patients, and that we can do that faster and more equitably,” Schukraft said. “The healthcare system is broken because it’s too many. We didn’t wait for it to be fixed, we made something better.”
And with Renacapavil currently in the mix, its “better” solution has evolved even further. Misttr is hoping to soon begin offering injectable preparation options and encourage interested patients to visit misttr.com Sign up.
“It’s absolutely possible to end HIV over the next few years,” Schcraft said. “But only if you get more people in the prep. With Lenacapavir and Misttr, we’re making one shot at a time in that future real.”
Source: Gayety – gayety.com
